Seek Returns

ALNY vs. BIO.B: Alnylam Pharmaceuticals vs. Bio-Rad Laboratories Stock Comparison

How do Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while BIO.B is classified in Life Sciences Tools & Services.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
Profile ItemALNYBIO.B
NameAlnylam Pharmaceuticals, Inc.Bio-Rad Laboratories, Inc. Class B Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization20.89 billion USD10.49 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2004September 21, 1999
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ALNY
BIO.B
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Total Return (1Y)-64.57%27.69%
Total Return (3Y, Annualized)-1.58%9.13%
Total Return (5Y, Annualized)-3.13%-12.33%

Risk Profile

Drawdown History

ALNY
BIO.B
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Alnylam Pharmaceuticals (ALNY) trades around 1.90M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Volatility (1Y, Annualized)54.08%30.96%
Beta (5Y)0.451.00
Max Drawdown (5Y)-68.25%-70.74%
Avg. Volume (3M)1.90M11

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ALNY and BIO.B are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Sharpe Ratio (1Y)-1.270.74
Sortino Ratio (1Y)-1.451.10

Profitability

ROE (TTM)

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Bio-Rad Laboratories (BIO.B) at 14.27% also sits in the top quartile.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY
138.07%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Bio-Rad Laboratories (BIO.B) at 39.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY
52.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max
83.12%
ALNY
23.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
ROE (TTM)138.07%14.27%
ROA (TTM)9.51%1.50%
Net Margin (TTM)52.85%39.45%
Operating Margin (TTM)23.72%9.46%
Gross Margin (TTM)77.28%52.19%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Bio-Rad Laboratories (BIO.B) at 0.65% is closer to the peer norm — faster top-line expansion for ALNY.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO.B) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Revenue Growth (YoY)65.19%0.65%
Revenue Growth (3Y CAGR)52.98%-2.68%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Bio-Rad Laboratories (BIO.B) at 3.18 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max
25.13
Q3
12.13
Median
5.52
ALNY
2.48
Q1
2.47
Min
0.10

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
1.42
ALNY
0.83
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Current Ratio (MRQ)2.483.18
Debt / Equity (MRQ)0.830.18
Net Debt / EBITDA-0.57-0.73

Dividends

Dividend Yield (TTM)

Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO.B) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO.B) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 7.88 and Bio-Rad Laboratories (BIO.B) at 10.36 sit in the cheaper earnings-multiple quartile for P/E ratio, with the market paying less for a dollar of trailing earnings than it pays for typical peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
ALNY
7.88
Min
0.07

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Bio-Rad Laboratories (BIO.B) at 4.05 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max
58.18
Q3
25.77
Median
7.30
ALNY
4.17
Q1
3.01
Min
0.01

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Alnylam Pharmaceuticals (ALNY) at 5.79 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max
13.53
Q3
6.54
ALNY
5.79
Median
3.25
Q1
1.69
Min
-5.59

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO.B)
MetricALNYBIO.B
P/E Ratio (TTM)7.8810.36
P/S Ratio (TTM)4.174.05
P/B Ratio (MRQ)5.791.38
Free Cash Flow Yield (TTM)1.57%2.59%